Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells
Y. Ishii et al., Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells, LEUK RES, 25(9), 2001, pp. 813-820
Various inhibitors of protein kinases regulate the growth and differentiati
on of human leukemic cell lines. The pyridinyl imidazole inhibitor SB203580
has been widely used to elucidate the role of p38 kinase in a wide array o
f biological systems, In the present investigation, we found that SB203580
effectively induced the granulocytic differentiation of human promyelocytic
HL-60 cells. In addition to morphological differentiation, it also induced
NBT-reduction, lysozyme activity and growth-inhibition. It also induced th
e differentiation of human myeloid leukemia HT93 and ML-1 cells, but not of
other cell lines, such as NB4, U937, THP-1, K562 and HEL. This differentia
tion was not associated with the inhibition of p38 kinase activity, but was
closely associated with the activation of extracellular signal- regulated
kinase. These results demonstrate a new activity for this drug. (C) 2001 El
sevier Science Ltd. All rights reserved.